You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)上季總產品收入逾16億人幣 按年增長逾65%
阿思達克 02-06 17:23
信達生物(01801.HK)公布,於去年第四季,公司共取得總產品收入逾16億元人民幣,按年增長逾65%。於季度內,達伯舒(信迪利單抗注射液)的適應症及國家醫保覆蓋持續拉動銷量快速增長,市場領先地位加強;產品組合愈加多元化,其他產品整體亦保持顯著增長。 於季度內,達伯舒(信迪利單抗注射液)新增第七項適應症及達攸同(貝伐珠單抗注射液)新增第八項適應症納入2023年版國家醫保藥品目錄,是中國唯一獲批用於EGFR-TKI治療失敗非小細胞肺癌的醫保PD-1抑制劑和醫保貝伐珠單抗。此外,公司2款創新腫瘤靶向藥物IBI-344(ROS1抑制劑)和IBI-351(KRAS G12C抑制劑)的新藥上市申請(NDA)獲國家藥品監督管理局(NMPA)受理並授予優先審評資格。 截至目前,公司已取得十款產品獲批上市,同時還有2個品種的NDA在NMPA審評中,5個新藥分子進入III期或關鍵性臨床研究,另外約20個新藥品種已進入臨床研究。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account